DDR1 as a key prognostic biomarker in non-small cell lung cancer: identification, validation, and potential therapeutic implications
Our study demonstrated that DDR1 promotes tumor progression and immune evasion and is frequently overexpressed in NSCLC patients, suggesting that DDR1 is a potential prognostic biomarker and therapeutic target.
Authors
- Dongdong Xv
- Xiaowei Sun (ORCID: https://orcid.org/0000-0003-1915-9161)
- Yue Cui (ORCID: https://orcid.org/0000-0002-4724-2598)
- ShaoBo Wang
- Qian Lü (ORCID: https://orcid.org/0000-0001-7271-5804)
- Ren-Cai Lu (ORCID: https://orcid.org/0000-0002-2742-4108)
- Jian-Fang ZHANG
- Hongwei Su
Institutions
- Kunming University of Science and Technology (CN)
- Kunming University (CN)
- First People's Hospital of Yunnan Province (CN)
- People's Liberation Army 401 Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-28
- DOI
- https://doi.org/10.3389/fimmu.2025.1690829
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Kunming University of Science and Technology
- Yunnan Provincial Science and Technology Department
- National Cancer Institute